Table 2.
Association of LAMP with CRC clinical parameters
| Number (N = 635) |
High-expression (N = 317) |
low-expression (N = 318) |
P value | |
|---|---|---|---|---|
| Age | 66.4 (12.7) | 65.1 (12.8) | 67.8 (12.6) | 0.008 |
| Gender | 0.292 | |||
| Female | 296 (46.6%) | 138 (43.5%) | 158 (49.7%) | |
| Male | 336 (52.9%) | 177 (55.8%) | 159 (50.0%) | |
| Location | 0.309 | |||
| COAD | 469 (73.9%) | 228 (71.9%) | 241 (75.8%) | |
| READ | 166 (26.1%) | 89 (28.1%) | 77 (24.2%) | |
| Histological type | 0.039 | |||
| Adenocarcinoma | 542 (85.4%) | 280 (88.3%) | 262 (82.4%) | |
| Mucinous | 79 (12.4%) | 29 (9.15%) | 50 (15.7%) | |
| T stage | 0.015 | |||
| T1 | 21 (3.31%) | 6 (1.89%) | 15 (4.72%) | |
| T2 | 108 (17.0%) | 43 (13.6%) | 65 (20.4%) | |
| T3 | 430 (67.7%) | 223 (70.3%) | 207 (65.1%) | |
| T4 | 72 (11.3%) | 42 (13.2%) | 30 (9.43%) | |
| N stage | <0.001 | |||
| N0 | 360 (56.7%) | 149 (47.0%) | 211 (66.4%) | |
| N1 | 152 (23.9%) | 94 (29.7%) | 58 (18.2%) | |
| N2 | 117 (18.4%) | 69 (21.8%) | 48 (15.1%) | |
| NX | 2 (0.31%) | 2 (0.63%) | 0 (0.00%) | |
| M stage | <0.001 | |||
| M0 | 469 (73.9%) | 208 (65.6%) | 261 (82.1%) | |
| M1 | 88 (13.9%) | 52 (16.4%) | 36 (11.3%) | |
| MX | 66 (10.4%) | 52 (16.4%) | 14 (4.40%) | |
| Tumor stage | <0.001 | |||
| I | 108 (17.0%) | 42 (13.2%) | 66 (20.8%) | |
| II | 233 (36.7%) | 95 (30.0%) | 138 (43.4%) | |
| III | 182 (28.7%) | 109 (34.4%) | 73 (23.0%) | |
| IV | 89 (14.0%) | 52 (16.4%) | 37 (11.6%) |